1 / 16

CNS depressants CNS depressants can be classified into :

CNS depressants CNS depressants can be classified into : I- Sedative hypnotics II- Anxiolytic drugs III- CNS depressants with skeletal muscle relaxant properties IV- Anticonvulsants V- Antipsychotics. I- Sedative hypnotics

ariana-dyer
Télécharger la présentation

CNS depressants CNS depressants can be classified into :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CNS depressants CNS depressants can be classified into: I- Sedative hypnotics II- Anxiolytic drugs III- CNS depressants with skeletal muscle relaxant properties IV- Anticonvulsants V- Antipsychotics I- Sedative hypnotics - Can be used to overcome insomnia (restlessness) - Cause drowsiness, initiation and/or maintenanceof sleep - Pharmacological effects are dose related: Dose: ↑Sedation ► Hypnosis ► Surgical anesthesia - No common structural features, include: 1- Barbiturates. 2- Chloral. 3- Ureides. 4- Piperidinediones. 5- Cyclopyrrolones 6- Imidazopyridines. 7- Benzodiazepines 8- Melatonin Receptor Agonist 9- Antihistamines

  2. 1- Barbiturates • The barbiturates are 5,5-disubstituted barbituric acids. • For good hypnotic activity, barbituric acid derivatives must be weak acids . • They must have lipid/water partition coefficient between certain limit. • The acidity of the barbiturates in aqueous solution depends on the • number of substituents attached to barbituric acid.

  3. MOA: • Enhance the GABA-ergic inhibitory response(as Benzodiazepines). • S.E. • Slowly eliminated barbiturates: hangover (overshadow) & psychomotor impairment (injury). • Nowbarbituratesget minimal use as sedatives & hypnotics (Why?) • They have higher toxicity, that cause greater CNS depression. • They induce many of the liver metabolizing enzymes. • Barbiturates cause tolerance and, often physical dependence. • N.B.: • When an individual addicted to barbiturates, sudden withdrawal should be • avoided, because it can cause grand mal seizures, which lead to a spasm • of the respiratory musculature, producingimpaired respiration, cyanosis, • and possibly death.

  4. 5,5,-disubstituted & 1,5,5-trisubstituted areactive SAR: All other substitution► inactive 1,3-disubstituted or 1,3,5,5-tetrasubstituted are inactiveor produce convulsions * Replacement of C-2ObyS → ↑ lipid solubility. Thiopental used as IV anesthetics due to rapid onset & quick brain levels achieved. * Introduction of more sulfur atoms (2,4-dithio derivatives) destroys potency, due to decreased hydrophilic character beyond required limits.

  5. 5,5-Disubstitution: • Both substituents shoud be between6-10 carbon. • Branching, unsaturation, replacement of alkyl withalicyclic or aromatic substituents,↑the lipid solubility leading to high potency. • Introduction of a halogen atom into the 5-alkyl substituent ↑ the potency. • Introduction of polar groups e.g. OH, NH2, RNH, CO, COOH and SO3H into the5-alkyl substituent ↓ the lipid solubility (may destroy potency). For hypnotic activity, the compound must be a weak acid with suitable log P. Substitution on nitrogen: • Substitution on one NH by alkyl gp ↑ lipid solubility ►quicker onset & shorter duration • As the N-alkyl increases in size, the lipid solubility increases, But larger alkyl groups (> methyl) ► convulsant properties. • Alkyl substitution on both N1 & N3renders the drug nonacidic (inactive).

  6. Classification • Barbiturates are classified according to their duration of action into: • Long duration of action (> 6 hours). • Intermediate durationof action (3-6 hours). • Short duration of action (< 3 hours). • Ultrashortduration of action (intravenous anesthetics). Onset up to 1 hourlasts about 12 hoursused for ; daytime sedation seldom used. - treatment of seizure disorders Long-Acting Barbiturates Daytime Sedatives and Typical Anticonvulsants

  7. used for : - insomnia.- preoperative sedation.- Anesthesia and euthanasia in animals Sedatives and Hypnotics used for - preoperative sedation.- insomnia (seldom used). Typical Sedatives and Hypnotics D. Ultra-Short-Acting Barbiturates • thiocarbonyl and C-5 side chain with 5 carbon unit • (ethyl or allyl e.g. Thiamylal CH2CH=CH2) Thiopental Induction Anaesthesia

  8. Synthesis of Barbiturates Barbiturate Abuse: • Prolonged useleads to habituation, (tolerance to increased doses and physical dependence). • Monooxygenaseenzymesynthesis is increased by repeated dose of phenobarbital (enzyme induction), therefore the drug will be rapidly metabolizedleading totolerance.

  9. Barbiturates - Metabolism An ultimate (Ω) or penultimate (Ω-1) oxidation of C-5 substituents Oxidation of substituent at C- 5 by CYP450’s Most Barbiturates Aromatic Hydroxylation Phenobarbital Mephobarbital Glucuronide and sulfate conjugates Slide 6

  10. Barbiturates - Metabolism Desulfuration Thiobarbiturates N-Dealkylation N-Methylbarbiturates Slide 7 Desulfuration of 2-thiobarbiturates to yield more hydrophilic barbiturates mephobarbital phenobarbital

  11. Barbiturates - Metabolism N-oxidation Most Barbiturates Hydrolysis Most Barbiturates hepatic metabolic inactivation Slide 5

  12. 2- Chloral (Chloral hydrate) Trichloroacetaldehyde monohydrate • Has no analgesic or tranquilizing effect & devoid of adverse respiratory effects • A weak acid (electron-withdrawing CCl3 group) ► irritating to stomach. • MOA: Trichloroethanol has barbiturate-like effects on the GABAA receptor. • Metabolism:1. Quickly reduced to trichloroethanol(hypnotic activity). 2. Quickly detoxified to the inactive trichloroacetic acid. Init. effect Inactive metabolite Prolonged effect

  13. 3- Ureides • OnlyAcetylcarbromal(1-Acetyl-3-(2-Bromo-2-ethyl-butyryl)-urea ) is still available. • Prolonged use is not recommended due to in vivo release of bromide ions (bromism) 4- Piperidinediones e. g.Methyprylon3,3-diethyl-5-methyl-2,4-piperidinedione • They are effective sedative-hypnotics,structurally related to barbiturates (Hence, many biological respects). 5- Cyclopyrrolones e. g.Zopiclone • A new hypnotic agent with no withdrawal symptoms (no accumulation on repeated administration). Metabolism: Major: less active,zopiclone N-oxide Minor: inactive, N-desmethylzopiclone

  14. 6- Imidazopyridines • e. g.Zolpidem • short t1/2 (rapid metabolic oxidation to inactive COOH acid metabolites. Nonbenzodiazepine GABAA Agonists: [Z drugs] zopiclone & zolpidem Advantages: • They are used as short-acting sedative-hypnotics. • They have high-affinity for GABAA receptors ~ to benzodiazepines. • They are highly lipophilic, so rapid absorption & distribution. • They have very little physical dependence & abuse potential.

  15. 7- Benzodiazepines • MOA:bind to specific binding sites in GABAA receptors. • Used as anxiolytics, hypnotics, anticonvulsants and muscle relaxants. • Advantages:OverBarbiturates: • Relative safety (no respiratory depression). Preferredfor patients with suicidal intentions. Fewer drug interactions. • Disadvantages: • Slowly eliminated due to active metabolites in blood and brain (hangover effect and accumulation on repeated dose).

  16. 8- Melatonin Receptor Agonist MT receptor play important role in discovery and approval of ramelteon. Ramelteon • It is effective in initiating sleep (shortening sleep latency) but not in maintaining sleep (has short half-life). • It is a very potent & very selective ligand for the MT1 receptor • used in the treatment of insomnia. • Does not bind with other receptors associated with sleep (GABAA or dopamine).

More Related